PCN73 REAL TOTAL COSTS ASSOCIATED WITH MULTIPLE MYELOMA: RESULT FROM SINGLE UPPER MIDDLE INCOME COUNTRY IN EU

Abstract

To follow-up on the previous cost calculations and calculate the real total costs associated with multiple myeloma (MM) in model patient in productive age from the confirmed diagnosis till death in single EU jurisdiction – Slovak Republic. To establish partnership with key state payers and stakeholders to obtain best possible real-life cost data associated with MM. We performed the retrospective analysis with the assistance of Ministry of Health, Ministry of Social Affairs, state General Insurance Company (VšZP) and other key stakeholders of total costs (direct and indirect) associated with MM. We used the “bottom-up” approach to identify, quantify and value resources in a disaggregated way, so that each element of the costs is estimated individually and summed up at the end. Total costs were calculated for a model patient with MM from diagnosis till death. According to all available resources provided by key stakeholders, the distribution of the total costs associated with MM (% from total costs, EUR 1 = USD 1.1332, European Central Bank) was as follows: direct health care costs €261 475 (64%, $296 303) and total indirect costs €147 596 (36%, $167 255). Total costs associated with model patient with MM in productive age was €409 071 ($463 559). Costs included e.g. treatment, hospitalizations or costs associated with the productivity loss due to premature death due to MM calculated for local conditions. We calculated unique data for MM in partnership with the key state payers and stakeholders. The focus was on MM patients in productive age that create almost 56% of all MM patients in Slovakia. Cost data accuracy and reliability due to verification of all cost data was very high and create important base for evaluation of existing and new innovations coming to MM segment.